Goal: To raise awaremenss of the implications of the new CMS erythropoietin claims policy.
Objectives:
Outline the history of reimbursement for erythropoietin claims for patients with chronic kidney disease.
Summarize 5 provisions included in the CMD reimbursement policy related to erythropoietin for patients with chronic kidney disease.
State the implications for the new CMS policy for erythropoietin claims for professionals involved in the care of those with chronic kidney disease.
Note: This article is supported by an unrestricted educational grant from Amgen. The manuscript has underhone peer review. The information does not necessarily reflect the opinions of ANNA or the sponsor.
